TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25832687

Group type: EXPERIMENTAL
Intervention: Induction chemotherapy with GCP (3 cycles of gemcitabine 1000 mg/m², carboplatin AUC 2.5, and paclitaxel 70 mg/m²) followed by concurrent chemo-radiation (radiation therapy 69.96 Gy with weekly cisplatin 40 mg/m²)
Number of subjects: 172

Group type: COMPARATOR
Intervention: Concurrent chemo-radiation alone (control)
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: Induction chemotherapy with GCP
Number of subjects: 172
Study: 23829029

Group type: EXPERIMENTAL
Intervention: Cylindrical handhold diameter of 3.81 cm
Number of subjects: 397

Group type: COMPARATOR
Intervention: Cylindrical handhold diameters (various sizes)
Number of subjects: 397

Group type: EXPERIMENTAL
Intervention: Grip strength, age, and hand breadth as covariates
Number of subjects: 397
Study: 21505224

Group type: EXPERIMENTAL
Intervention: Emergency care practitioners (ECPs)
Number of subjects: 1163
Study: 19654536

Group type: EXPERIMENTAL
Intervention: Oral acyclovir administered during the first 6 months after penetrating keratoplasty
Number of subjects: 47

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study: 16731723

Group type: EXPERIMENTAL
Intervention: 14‐day healthy longevity lifestyle program combining a brain healthy diet plan, relaxation exercises, cardiovascular conditioning, and mental exercise (brain teasers and verbal memory training techniques)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Usual lifestyle routine
Number of subjects: 17
Study: 15536141

Group type: EXPERIMENTAL
Intervention: Intraperitoneal cefazolin and ceftazidime (15 mg/kg rounded to nearest 100 mg)
Number of subjects: 13

Group type: COMPARATOR
Intervention: No antibiotic (Phase I)
Number of subjects: 13
Study: 10823386

Group type: EXPERIMENTAL
Intervention: Catecholamines (epinephrine, norepinephrine, isoproterenol, and dopamine)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Phosphodiesterase inhibitors
Number of subjects: 0

Group type: COMPARATOR
Intervention: Supranormal oxygen delivery
Number of subjects: 0
Study: 9071292

Group type: EXPERIMENTAL
Intervention: Nomogram-guided group
Number of subjects: 39

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 39
Study: 8261298

Group type: EXPERIMENTAL
Intervention: 2-sphere plug
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 1-sphere plug
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both plugs
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Urethral plug treatment
Number of subjects: 40
Study: 3899047

Group type: EXPERIMENTAL
Intervention: Monoamine oxidase inhibitors (MAOIs) - clorgyline or tranylcypromine sulfate
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Dextroamphetamine sulfate
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo (during washout period)
Number of subjects: 14
Study: 29985095

Group type: EXPERIMENTAL
Intervention: Mindfulness-based stress reduction (MBSR)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Education control
Number of subjects: 62
Study: 26122803

Group type: EXPERIMENTAL
Intervention: Umbilical Cord Milking (UCM)
Number of subjects: 154

Group type: COMPARATOR
Intervention: Delayed Cord Clamping (DCC)
Number of subjects: 154
Study: 24298907

Group type: EXPERIMENTAL
Intervention: Three-drug regimen (clarithromycin, ethambutol, and rifampicin)
Number of subjects: 119

Group type: COMPARATOR
Intervention: Two-drug regimen (clarithromycin and ethambutol)
Number of subjects: 119
Study: 22116196

Group type: EXPERIMENTAL
Intervention: Allopurinol (100‐300 mg/day)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Usual therapy
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Allopurinol
Number of subjects: 40
Study: 18930189

Group type: EXPERIMENTAL
Intervention: NGM/EE 25 microg
Number of subjects: 0

Group type: COMPARATOR
Intervention: NETA/EE 20 microg
Number of subjects: 0
Study: 17440125

Group type: EXPERIMENTAL
Intervention: Traditional weekly sessions
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Minimal-therapist-contact sessions
Number of subjects: 91

Group type: COMPARATOR
Intervention: Waiting-list control group
Number of subjects: 91
Study: 16138585

Group type: EXPERIMENTAL
Intervention: Huorongbushen 48 g daily for 3 months
Number of subjects: 86

Group type: COMPARATOR
Intervention: Indomethacin 50 mg daily for 3 months
Number of subjects: 86
Study: 12503835

Group type: EXPERIMENTAL
Intervention: risperidone (4 mg)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: olanzapine (10 mg)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: thioridazine (50 mg)
Number of subjects: 16

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 16
Study: 9796042

Group type: EXPERIMENTAL
Intervention: Acellular five‐component vaccine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Acellular two‐component vaccine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Licensed US whole cell vaccine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Multicomponent pertussis vaccines
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Anti-pertactin, anti-fimbriae 2/3, and anti-PT
Number of subjects: 0
Study: 7653464

Group type: EXPERIMENTAL
Intervention: Lifestyle interventions
Number of subjects: 0
Study: 1671890

Group type: EXPERIMENTAL
Intervention: Oral nystatin
Number of subjects: 24

Group type: COMPARATOR
Intervention: No treatment (antibacterial agents withdrawn)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Continuation of antibacterial therapy (without candida overgrowth)
Number of subjects: 24
Study: 6186329

Group type: EXPERIMENTAL
Intervention: Intravenous atenolol followed by oral atenolol (5 mg IV, then 50 mg oral, 50 mg oral 12 hours later, then 100 mg daily for 10 days)
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: Intravenous atenolol
Number of subjects: 182

Group type: COMPARATOR
Intervention: Control group (no atenolol)
Number of subjects: 182
Study: 31565794

Group type: EXPERIMENTAL
Intervention: Real-time feedback during CPR training
Number of subjects: 115

Group type: COMPARATOR
Intervention: No real-time feedback during CPR training (Control)
Number of subjects: 115
Study: 30353790

Group type: EXPERIMENTAL
Intervention: Living Well intervention
Number of subjects: 242

Group type: COMPARATOR
Intervention: Active control group
Number of subjects: 242

Group type: EXPERIMENTAL
Intervention: Emergency room use
Number of subjects: 242
Study: 30463527

Group type: EXPERIMENTAL
Intervention: Nutritional supplement
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Physical activity program
Number of subjects: 0
Study: 26885786

Group type: EXPERIMENTAL
Intervention: Ixekizumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sleep Problems Index I
Number of subjects: 0
Study: 24679882

Group type: COMPARATOR
Intervention: Shock wave lithotripsy (Group 1)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Retrograde intrarenal surgery (Group 2)
Number of subjects: 60
Study: 22154461

Group type: EXPERIMENTAL
Intervention: Cushing syndrome treatment (surgical cure)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (age and body mass index-matched)
Number of subjects: 30
Study: 19744828

Group type: COMPARATOR
Intervention: DiaPep277 (immune intervention)
Number of subjects: 99
Study: 18763197

Group type: EXPERIMENTAL
Intervention: Vacuum-assisted closure (VAC)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (classic treatment)
Number of subjects: 20
Study: 16182105

Group type: EXPERIMENTAL
Intervention: Oral diazepam, 5 mg (n = 17, study group)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Sublingual captopril, 25 mg (n = 19, control group)
Number of subjects: 36
Study: 12597676

Group type: EXPERIMENTAL
Intervention: Patented chamomile preparation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Hydrocortisone
Number of subjects: 0
Study: 10092302

Group type: EXPERIMENTAL
Intervention: 180 mg urease + 5 microg heat-labile enterotoxin (LT)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: 60 mg urease + 5 microg heat-labile enterotoxin (LT)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo + LT
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Urease (any dose)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Urease immunization
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 26
Study: 7517172

Group type: EXPERIMENTAL
Intervention: LNH-84 or LNH-87 regimen
Number of subjects: 48
Study: 2538050

Group type: EXPERIMENTAL
Intervention: 10 or 15 g of soy polysaccharide fiber
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 15 g of soy polysaccharide fiber
Number of subjects: 0

Group type: COMPARATOR
Intervention: Fiber-free meal
Number of subjects: 0
Study: 140827

Group type: EXPERIMENTAL
Intervention: Tofranil (25 mg three times a day for four weeks)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Tofranil
Number of subjects: 59
Study: 30536191

Group type: EXPERIMENTAL
Intervention: Patented perfusion and suctioning platform and ureteral access sheath
Number of subjects: 122

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 122
Study: 28585859

Group type: EXPERIMENTAL
Intervention: Patiromer 25.2 g coadministered with victim drugs
Number of subjects: 370

Group type: EXPERIMENTAL
Intervention: Patiromer 25.2 g coadministered with levothyroxine
Number of subjects: 370

Group type: EXPERIMENTAL
Intervention: Patiromer 25.2 g coadministered with metformin
Number of subjects: 370

Group type: EXPERIMENTAL
Intervention: Patiromer 25.2 g coadministered with ciprofloxacin
Number of subjects: 370

Group type: EXPERIMENTAL
Intervention: Patiromer 25.2 g coadministered with various drugs
Number of subjects: 370

Group type: EXPERIMENTAL
Intervention: Patiromer 25.2 g administered 3 hours after victim drugs
Number of subjects: 370

Group type: EXPERIMENTAL
Intervention: Patiromer 25.2 g coadministered with ciprofloxacin, levothyroxine, and metformin
Number of subjects: 370
Study: 25749297

Group type: EXPERIMENTAL
Intervention: Darapladib 160 mg once daily for 3 months
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study: 23807837

Group type: EXPERIMENTAL
Intervention: Multimodal microemulsion (formulation A)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Minoxidil alone (formulation B)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo (formulation C)
Number of subjects: 32
Study: 20193777

Group type: EXPERIMENTAL
Intervention: Culturally tailored interactive stroke preparedness strategy
Number of subjects: 736

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 736
Study: 17643339

Group type: EXPERIMENTAL
Intervention: Push up on Swiss ball
Number of subjects: 10

Group type: COMPARATOR
Intervention: Push up on Bench
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Push up plus on Swiss ball
Number of subjects: 10

Group type: COMPARATOR
Intervention: Push up plus on Bench
Number of subjects: 10
Study: 16339791

Group type: EXPERIMENTAL
Intervention: Warmed lidocaine (40 degrees C) 1% intra-articularly 20 min before surgery
Number of subjects: 2

Group type: COMPARATOR
Intervention: Room-temperature lidocaine (25 degrees C) 1% intra-articularly 20 min before surgery
Number of subjects: 2

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 2
Study: 12584283

Group type: EXPERIMENTAL
Intervention: Sevelamer hydrochloride (initial dose: 2.4 g/day, increased to 4.4 g/day)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Calcium carbonate (4.8 g/day)
Number of subjects: 42
Study: 11357004

Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) treatment at 0.1 IU/kg
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) treatment at 0.2 IU/kg
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) treatment at 0.3 IU/kg
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: High-dose GH treatment (0.3 IU/kg) interrupted
Number of subjects: 78
Study: 8635106

Group type: EXPERIMENTAL
Intervention: Risk counseling intervention
Number of subjects: 987
Study: 1589558

Group type: EXPERIMENTAL
Intervention: Ethanol 0.9 g/kg body weight
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Diazepam 10 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Flunitrazepam 1 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Diazepam 20 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Flunitrazepam 2 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Flunitrazepam 1 mg and Diazepam 20 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Flunitrazepam treatments
Number of subjects: 12
Study: 3898689

Group type: EXPERIMENTAL
Intervention: Metyrapone (0.5-2.5 g/day)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Aminoglutethimide (0.5-1.5 g/day)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Combination of metyrapone and aminoglutethimide
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Metyrapone
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Aminoglutethimide
Number of subjects: 15
Study: 31664452

Group type: EXPERIMENTAL
Intervention: Question Prompt List (QPL) intervention
Number of subjects: 446

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 446

Group type: EXPERIMENTAL
Intervention: QPL intervention (restricted to patients who reviewed the QPL)
Number of subjects: 446
Study: 29091001

Group type: EXPERIMENTAL
Intervention: 16-gauge biopsy
Number of subjects: 150

Group type: COMPARATOR
Intervention: 18-gauge biopsy
Number of subjects: 150
Study: 27346646

Group type: EXPERIMENTAL
Intervention: HIIT (4×4min 90% of peak heart rate; HRpeak)
Number of subjects: 51

Group type: COMPARATOR
Intervention: MICT (isocaloric at 70% of HRpeak)
Number of subjects: 51

Group type: COMPARATOR
Intervention: CONT (non-exercise control)
Number of subjects: 51
Study: 25397803

Group type: EXPERIMENTAL
Intervention: Screw-retained group (SRG)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Cement-retained group (CRG)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 28
Study: 23540189

Group type: EXPERIMENTAL
Intervention: rHuEPO (200 IU/kg/dose subcutaneously every alternate day for 2 weeks)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control (no rHuEPO, received oral iron and folic acid from day 14)
Number of subjects: 60
Study: 20590723

Group type: EXPERIMENTAL
Intervention: Upright faces of 5-year-old children, adults, and elderly adults
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Inverted faces
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Other-age faces
Number of subjects: 3
Study: 18922383

Group type: EXPERIMENTAL
Intervention: Flecainide 200 mg/day
Number of subjects: 123

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 123
Study: 15795816

Group type: EXPERIMENTAL
Intervention: Creatine monohydrate 10 g daily
Number of subjects: 175

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 175
Study: 12091294

Group type: EXPERIMENTAL
Intervention: Moderately early postnatal dexamethasone treatment (4.75 mg/kg over 14 days from the 10th day of life)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Untreated group (control)
Number of subjects: 30
Study: 10929979

Group type: EXPERIMENTAL
Intervention: Polyglactin sutures
Number of subjects: 30

Group type: COMPARATOR
Intervention: Nylon sutures
Number of subjects: 30
Study: 7854168

Group type: COMPARATOR
Intervention: Recombinant human growth hormone (rhGH) at a dose of 0.25 to 0.5 U/kg/wk, administered subcutaneously once a day in the evening.
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control group (not specified in detail).
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Recombinant human growth hormone (rhGH) treatment.
Number of subjects: 10
Study: 1835837

Group type: EXPERIMENTAL
Intervention: counseling at the acute stage
Number of subjects: 117
Study: 7140140

Group type: EXPERIMENTAL
Intervention: Smoking + work
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Smoking
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: No smoking + work
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: No smoking
Number of subjects: 0
Study: 31853727

Group type: EXPERIMENTAL
Intervention: Technician-guided ICBT (n = 42)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Self-guided ICBT (n = 44)
Number of subjects: 86
Study: 29939043

Group type: EXPERIMENTAL
Intervention: School-based mentoring
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Improved relationship quality in mentoring
Number of subjects: 0
Study: 30197808

Group type: EXPERIMENTAL
Intervention: Septoplasty
Number of subjects: 50
Study: 26848117

Group type: EXPERIMENTAL
Intervention: Bed-sharing 'often'
Number of subjects: 870

Group type: EXPERIMENTAL
Intervention: Bed-sharing 'intermittently'
Number of subjects: 870

Group type: EXPERIMENTAL
Intervention: Bed-sharing 'rarely' or 'never'
Number of subjects: 870

Group type: EXPERIMENTAL
Intervention: Strong prenatal breastfeeding intent
Number of subjects: 870

Group type: EXPERIMENTAL
Intervention: High prenatal importance to breastfeeding
Number of subjects: 870
Study: 24163187

Group type: EXPERIMENTAL
Intervention: Loss-framed messages
Number of subjects: 0

Group type: COMPARATOR
Intervention: Gain-framed messages
Number of subjects: 0

Group type: COMPARATOR
Intervention: No messages
Number of subjects: 0
Study: 22108473

Group type: COMPARATOR
Intervention: Compression stockings (group 1)
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Pycnogenol® (group 2)
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Combination of Pycnogenol® and compression stockings (group 3)
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Pycnogenol®
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Combination of Pycnogenol® and compression stockings
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Pycnogenol® plus stockings
Number of subjects: 156

Group type: COMPARATOR
Intervention: All groups
Number of subjects: 156

Group type: COMPARATOR
Intervention: Compression stockings and Pycnogenol®
Number of subjects: 156

Group type: COMPARATOR
Intervention: Laser Doppler flowmetry
Number of subjects: 156
Study: 19675206

Group type: EXPERIMENTAL
Intervention: Continuous Glucose Monitoring (CGM)
Number of subjects: 232
Study: 17224195

Group type: EXPERIMENTAL
Intervention: 3D intensity modulated radiotherapy (IMRT)
Number of subjects: 306

Group type: COMPARATOR
Intervention: Standard 2D radiotherapy
Number of subjects: 306
Study: 15588339

Group type: EXPERIMENTAL
Intervention: Emtricitabine (FTC) 25 mg qd
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Emtricitabine (FTC) 100 mg qd
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Emtricitabine (FTC) 200 mg qd
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Emtricitabine (FTC) 200 mg bid
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Emtricitabine (FTC) 200 mg qd in HIV-infected patients
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Emtricitabine (FTC) in healthy volunteers
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Emtricitabine (FTC) 200 mg/day
Number of subjects: 0
Study: 11907840

Group type: EXPERIMENTAL
Intervention: Betamethasone valerate foam (BMV foam), 0.12%, applied twice daily for 12 weeks
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo foam, applied twice daily for 12 weeks
Number of subjects: 40
Study: 9735502

Group type: EXPERIMENTAL
Intervention: Triple therapy with protease inhibitors (PI)
Number of subjects: 167
Study: 7523961

Group type: EXPERIMENTAL
Intervention: Transurethral microwave thermotherapy (TUMT)
Number of subjects: 130
Study: 3365458

Group type: EXPERIMENTAL
Intervention: MK-212 20 mg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: MK-212 40 mg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: MK-212 (10, 20, 40 mg)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 31982495

Group type: EXPERIMENTAL
Intervention: Thermal imaging at fraction 5 (fx = 5)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Thermal imaging at fraction 10 (fx = 10)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Random forest classifier model
Number of subjects: 90
Study: 29940335

Group type: EXPERIMENTAL
Intervention: HF-SMA (shared medical appointments)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study: 27065472

Group type: EXPERIMENTAL
Intervention: Anodal transcranial direct current stimulation (tDCS)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Sham transcranial direct current stimulation (tDCS)
Number of subjects: 14
Study: 26566367

Group type: EXPERIMENTAL
Intervention: rhTM (recombinant human soluble thrombomodulin)
Number of subjects: 22

Group type: COMPARATOR
Intervention: non-rhTM (control group)
Number of subjects: 22
Study: 23511562

Group type: EXPERIMENTAL
Intervention: Tamoxifen plus aminoglutethimide
Number of subjects: 1509

Group type: COMPARATOR
Intervention: Tamoxifen
Number of subjects: 1509
Study: 20457949

Group type: EXPERIMENTAL
Intervention: Contact lens correction
Number of subjects: 114

Group type: COMPARATOR
Intervention: Primary intraocular lens (IOL) implantation
Number of subjects: 114
Study: 18677672

Group type: EXPERIMENTAL
Intervention: Foot orthosis provided by the CAD‐CAM method
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Foot orthosis provided by the foam impression method
Number of subjects: 30

Group type: COMPARATOR
Intervention: Flat insole
Number of subjects: 30
Study: 16945169

Group type: EXPERIMENTAL
Intervention: High-dose levamisole combined with 5-FU and leucovorin
Number of subjects: 878

Group type: COMPARATOR
Intervention: Standard-dose levamisole combined with 5-FU and leucovorin
Number of subjects: 878
Study: 14529939

Group type: EXPERIMENTAL
Intervention: Melphalan 100 mg/m2 (three to four doses at 8- to 12-week intervals)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Cyclophosphamide 2 to 4 g/m2 (one or two cycles prior to stem cell collection)
Number of subjects: 13
Study: 11099390

Group type: EXPERIMENTAL
Intervention: 100% O(2)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 5% CO(2) (with 12% O(2))
Number of subjects: 12

Group type: COMPARATOR
Intervention: Air
Number of subjects: 12